November 3, 2011 – New study indicates strong diagnostic ability of treadmill exercise stress testing to uncover Long QT syndrome (LQTS) in patients.  Here, investigators from the Mayo Clinic show how the recovery phase displays significant and maladaptive changes in the QTc unveiling the most common LQTS type, LQT1. The study, published in the November edition of HeartRhythm, the official journal of the Heart Rhythm Society, is the largest, single-center study of treadmill exercise stress testing in patients with genetically proven LQTS as well as those who were dismissed as normal.

The U.S. Food and Drug Administration (FDA) today approved the first transcatheter aortic heart valve in the United States - the Sapien THV. Experts say the approval will open a new chapter in how patients with severe aortic valve stenosis will be treated, without surgery.

The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The stent uses the same drug and biocompatible polymer as the Xience V everolimus-eluting coronary stent system, but features an enhanced stent design and a delivery system designed for greater flexibility, better radial strength, longitudinal strength and more accurate stent placement.

November 1, 2011 – Claret Medical Inc. said its Montage System has received CE mark approval as the world's first complete system of filtration to protect both carotid arteries simultaneously. The 6 French catheter is delivered via radial or brachial access, providing complete neuro protection during intravascular procedures such as transcatheter aortic valve intervention (TAVI). The unique design of the Montage System not only provides neuro-protection from debris, but also captures and removes potential stroke-causing embolic material from the body.

November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, scheduled for Nov. 7-11 in San Francisco. TCT is designed to provide new insights for physicians who treat patients with cardiovascular disease and other vascular health issues.

Subscribe Now